MedTrace Logo

ctDNA Methylation Application in Postoperative Relapse and Adjuvant Chemotherapy Efficacy Evaluation

NCT05536089 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2024-05-22

No results posted yet for this study

Summary

In this study, the investigators aimed to apply their previously developed multi-locus blood-based assay targeting circulating tumor DNA methylation to monitor postoperative relapse and evaluate adjuvant chemotherapy efficacy in resected stage I and stage II (without high risk) colorectal cancer after radical resection.

Conditions

  • Cancer Colorectal

Interventions

DIAGNOSTIC_TEST

a multi-locus blood-based assay

Colorectal tumor-specific plasma ctDNA methylation markers detection

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    collaborator OTHER

  • Singlera Genomics Inc.

    lead INDUSTRY

Principal Investigators

  • KeFeng Ding, Ph.D · Second Affiliated Hospital, School of Medicine, Zhejiang University

  • Rui Liu, Ph.D · Singlera Genomics Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-05
Primary Completion
2028-09-30
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05536089 on ClinicalTrials.gov